Hippocampal Amyloid-Beta And Tau Distributions Differentially Affect Cognition In Centenarians

Journal Article (2025)
Author(s)

Susan K. Rohde (Amsterdam UMC, Vrije Universiteit Amsterdam)

Maruelle C. Luimes (Vrije Universiteit Amsterdam, Amsterdam UMC)

Annemieke J.M. Rozemuller (Netherlands Institute for Neuroscience, Amsterdam UMC)

Marieke J.I. Graat (Amsterdam UMC)

Myke E. van der Hoorn (Amsterdam UMC)

Dominique A.H. Daatselaar (Amsterdam UMC)

Marc Hulsman (Amsterdam UMC, Vrije Universiteit Amsterdam)

Sietske A.M. Sikkes (Vrije Universiteit Amsterdam, Amsterdam UMC)

Henne Holstege (Katholieke Universiteit Leuven, Amsterdam UMC, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, TU Delft - Electrical Engineering, Mathematics and Computer Science)

undefined More Authors

Department
Intelligent Systems
DOI related publication
https://doi.org/10.1002/alz70855_096283 Final published version
More Info
expand_more
Publication Year
2025
Language
English
Department
Intelligent Systems
Journal title
Alzheimer's & dementia : the journal of the Alzheimer's Association
Issue number
Suppl. 1
Volume number
21
Article number
e096283
Downloads counter
62
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Background
The hippocampus is differentially affected in Alzheimer's disease neuropathologic change (ADNC) versus primary age-related tauopathy (PART), an amyloid-beta (Aβ)-independent tauopathy: the CA2/CA1 hyperphosphorylated tau (pTau)-ratio is higher in PART, which inversely correlates with Aβ-burden. However, as the aging brain often presents mixed rather than uniform pathologies, we questioned whether these distinct hippocampal pTau distributions persist into extreme ages and how hippocampal Aβ- and pTau-distributions correlate with cognition in centenarians.

Method
We quantified Aβ- (6F/3D) and pTau (AT8)-burdens across eight hippocampal and parahippocampal subregions in 112 centenarians (median age 104, IQR 102-105), alongside 11 AD (median age 84, IQR 72-86) and 7 PART cases for comparison (median age 88, IQR 78-92; Figure 1). We compared CA2/CA1-pTau-ratio in centenarians who met PART criteria (Thal phase ≤2, Braak stage I-IV; n = 49) with centenarians who met ADNC criteria (intermediate/high according to NIA-AA guidelines; Thal phase ≥3, Braak stage III-VI; n = 50). Cognitive performance was assessed using 13 neuropsychological tests shortly before brain donation (median 10 months, IQR5-14, n = 72). Robust linear regression models were used to associate subregional Aβ- and pTau-burdens with cognitive performance, while adjusting for age, sex, and education.

Result
In line with previous findings, CA2/CA1-pTau-ratios were higher in younger PART cases compared to AD patients (median 3.0, IQR 2.1-3.6, min-max 1.6-4.2 vs. median 1.2, IQR 0.9-1.4, min-max 0.8-1.4; p <0.001). Surprisingly, CA2/CA1-pTau-ratios in centenarians with PART were comparable to centenarians with ADNC (median 1.3, IQR 1.1-2.0, min-max 0.3-10.8 vs. median 1.2, IQR 1.0-1.8, min-max 0.2-6.2; p = 0.684). Accordingly, CA2/CA1-pTau-ratio in centenarians was unrelated to Aβ-burden, Thal phase or Braak stage. Higher Aβ- and pTau-burdens associated with lower cognition, though through different subregions: cognition associated with Aβ-burden in the hippocampus (CA4, CA3, CA2, CA1/subiculum), whereas pTau-burden in the parahippocampus (presubiculum, entorhinal cortex, fusiform gyrus) associated with cognition.

Conclusion
In the oldest-old, PART and ADNC are less distinguishable by determinants observed in younger individuals: centenarians with ADNC may show age-related Aβ accumulation alongside PART-like pTau patterns, while centenarians meeting PART criteria do not always show PART-like pTau patterns. However, hippocampal Aβ-burden and parahippocampal pTau-burden associate with cognitive decline, highlighting subregional-specific vulnerability to pathology-driven cognitive decline.